Turagam MK, Musikantow D, Whang W, et al. - Via this systematic review and meta-analysis, researchers assessed safety as well as efficacy of atrial fibrillation (AF) ablation as first-line therapy, relative to antiarrhythmic drugs, in patients suffering from paroxysmal AF. Relevant randomized clinical trials (RCTs) were identified from PubMed/MEDLINE, Scopus, Google Scholar, and several major scientific conference sessions. Overall, six eligible RCTs consisting of 1212 patients were analyzed. Findings demonstrated that reductions in recurrence of atrial arrhythmias and hospitalizations were conferred by catheter ablation, vs antiarrhythmic drugs, with no difference in major adverse events when employed as first-line therapy of patients with paroxysmal AF.